Cargando…

Smaller bladder capacity and stronger bladder contractility in patients with ketamine cystitis are associated with elevated TRPV1 and TRPV4

Stronger contractility and smaller bladder capacity are common symptoms in ketamine cystitis (KC). This study investigates the association between expression levels of transient receptor potential cation channel subfamily V (TRPV) proteins and the clinical characteristics of KC. Bladder tissues were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Hsueh-Hui, Jhang, Jia-Fong, Hsu, Yung-Hsiang, Jiang, Yuan-Hong, Zhai, Wei-Jun, Kuo, Hann-Chorng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933333/ https://www.ncbi.nlm.nih.gov/pubmed/33664402 http://dx.doi.org/10.1038/s41598-021-84734-4

Ejemplares similares

Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease
por: Jhang, Jia-Fong, et al.
Publicado: (2016)

Usefulness of Urinary Biomarkers for Assessing Bladder Condition and Histopathology in Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Dysregulation of bladder corticotropin-releasing hormone receptor in the pathogenesis of human interstitial cystitis/bladder pain syndrome
por: Jhang, Jia-Fong, et al.
Publicado: (2019)

Possible Association between Bladder Wall Morphological Changes on Computed Tomography and Bladder-Centered Interstitial Cystitis/Bladder Pain Syndrome
por: Jhang, Jia-Fong, et al.
Publicado: (2021)

Pathophysiology, clinical presentation, and management of ketamine-induced cystitis
por: Jhang, Jia-Fong, et al.
Publicado: (2023)

Current Understanding of the Pathophysiology and Novel Treatments of Interstitial Cystitis/Bladder Pain Syndrome
por: Jhang, Jia-Fong, et al.
Publicado: (2022)

Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm
por: Jiang, Yuan-Hong, et al.
Publicado: (2021)

The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Sensory Receptor, Inflammatory, and Apoptotic Protein Expression in the Bladder Urothelium of Patients with Different Subtypes of Interstitial Cystitis/Bladder Pain Syndrome
por: Jiang, Yuan-Hong, et al.
Publicado: (2023)

Difference in electron microscopic findings among interstitial cystitis/bladder pain syndrome with distinct clinical and cystoscopic characteristics
por: Lee, Yu Khun, et al.
Publicado: (2021)

Use of Urinary Cytokine and Chemokine Levels for Identifying Bladder Conditions and Predicting Treatment Outcomes in Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Yu, Wan-Ru, et al.
Publicado: (2022)

Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition
por: Jhang, Jia-Fong, et al.
Publicado: (2018)

Can We Use Urinary Cytokine/Chemokine Analysis in Discriminating Ulcer-Type Interstitial Cystitis/Bladder Pain Syndrome?
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Urine Oxidative Stress Biomarkers as Novel Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Ultrastructural changes in the underactive bladder
por: Ho, Han-Chen, et al.
Publicado: (2020)

Use of Urinary Biomarkers in Discriminating Interstitial Cystitis/Bladder Pain Syndrome from Male Lower Urinary Tract Dysfunctions
por: Yu, Wan-Ru, et al.
Publicado: (2023)

Therapeutic Efficacy of Intravesical Platelet-Rich Plasma Injections for Interstitial Cystitis/Bladder Pain Syndrome—A Comparative Study of Different Injection Number, Additives and Concentrations
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Changes in the Ultrastructure of the Bladder Urothelium in Patients with Interstitial Cystitis after Intravesical Injections of Platelet-Rich Plasma
por: Lee, Yu-Khun, et al.
Publicado: (2022)

Treatment Outcomes of Intravesical Botulinum Toxin A Injections on Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Yu, Wan-Ru, et al.
Publicado: (2022)

Discriminating Different Bladder and Bladder Outlet Dysfunctions by Urinary Biomarkers in Women with Frequency–Urgency Syndrome
por: Jhang, Jia-Fong, et al.
Publicado: (2023)

Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients With Interstitial Cystitis/Bladder Pain Syndrome After Intravesical Platelet-Rich Plasma Injection
por: Jhang, Jia-Fong, et al.
Publicado: (2022)

Corrigendum: Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients With Interstitial Cystitis/Bladder Pain Syndrome After Intravesical Platelet-Rich Plasma Injection
por: Jhang, Jia-Fong, et al.
Publicado: (2022)

Potential urine biomarkers in bladder outlet obstruction-related detrusor underactivity
por: Jiang, Yuan-Hong, et al.
Publicado: (2021)

Multimodal Treatment with Cognitive Behavioral Therapeutic Intervention Plus Bladder Treatment Is More Effective than Monotherapy for Patients with Interstitial Cystitis/Bladder Pain Syndrome—A Randomized Clinical Trial
por: Yu, Wan-Ru, et al.
Publicado: (2022)

TRPV4 as a target for bladder overactivity
por: Angelico, Patrizia, et al.
Publicado: (2010)

Clinical Correlation of Bladder Electron Microscopic Characteristics in Patients with Detrusor Underactivity of Various Etiologies
por: Jhang, Jia-Fong, et al.
Publicado: (2022)

Low-Energy Shock Wave Plus Intravesical Instillation of Botulinum Toxin A for Interstitial Cystitis/Bladder Pain Syndrome: Pathophysiology and Preliminary Result of a Novel Minimally Invasive Treatment
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection
por: Jhang, Jia-Fong, et al.
Publicado: (2015)

Novel Applications of Non-Invasive Intravesical Botulinum Toxin a Delivery in the Treatment of Functional Bladder Disorders
por: Jhang, Jia-Fong, et al.
Publicado: (2021)

Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis
por: Chen, Jing-Liang, et al.
Publicado: (2020)

Current pharmacological and surgical treatment of underactive bladder
por: Jiang, Yuan-Hong, et al.
Publicado: (2017)

Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis—Different Mechanisms of Action of Botox on Bladder Dysfunction?
por: Kuo, Yuh-Chen, et al.
Publicado: (2016)

Revisiting the Role of Potassium Sensitivity Testing and Cystoscopic Hydrodistention for the Diagnosis of Interstitial Cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2016)

Effect of SQW on the bladder function of mice lacking TRPV1
por: Lai, Huanling, et al.
Publicado: (2016)

TRPV4 Mediates Acute Bladder Responses to Bacterial Lipopolysaccharides
por: Alpizar, Yeranddy A., et al.
Publicado: (2020)

Changes to the bladder epithelial barrier are associated with ketamine-induced cystitis
por: Duan, Qixin, et al.
Publicado: (2017)

Comparison of bladder autoaugmentation by transurethral vesicomyotomy and hydrodistention for ketamine cystitis
por: Tan, Shuo, et al.
Publicado: (2021)

TRPV4 mediates afferent pathways in the urinary bladder. A spinal c-fos study showing TRPV1 related adaptations in the TRPV4 knockout mouse
por: Janssen, Dick A. W., et al.
Publicado: (2016)

Inflammation and Barrier Function Deficits in the Bladder Urothelium of Patients with Chronic Spinal Cord Injury and Recurrent Urinary Tract Infections
por: Wu, Shu-Yu, et al.
Publicado: (2022)

Abnormal Sensory Protein Expression and Urothelial Dysfunction in Ketamine-Related Cystitis in Humans
por: Tsai, Yao Chou, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l85u6i98kocvk921u9elo8bu2e